Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Ferrer

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
European Urology Oncology|March 1, 2024
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer PatientsNatalia Jiménez, Marta Garcia de Herreros, Òscar Reig, et al.
NPJ Vaccines|September 29, 2023
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2Lorna Leal, Judit Pich, Laura Ferrer, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|November 9, 2023
Guidelines for establishing a cytometry laboratoryAnna C Belkina, Caroline E Roe, Vera A Tang, et al.
Breast Cancer Research and Treatment|February 24, 2025
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practiceMiriam Potrony, Blai Morales-Romero, Lorena Moreno, et al.
Iscience|February 7, 2023
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Antonio Barreiro, Antoni Prenafeta, Gregori Bech-Sabat, et al.
Journal of Youth and Adolescence|April 9, 2025
Global Profiles of Positive Youth Development: A Person-Oriented Analysis among Emerging Adults Living in 21 CountriesJet Uy Buenconsejo, Laura Ferrer-Wreder, Radosveta Dimitrova, et al.
Vaccine|January 14, 2025
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
The Lancet Regional Health. Europe|May 3, 2023
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
European Urology Oncology|March 1, 2024
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer PatientsNatalia Jiménez, Marta Garcia de Herreros, Òscar Reig, et al.
NPJ Vaccines|September 29, 2023
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2Lorna Leal, Judit Pich, Laura Ferrer, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|November 9, 2023
Guidelines for establishing a cytometry laboratoryAnna C Belkina, Caroline E Roe, Vera A Tang, et al.
Breast Cancer Research and Treatment|February 24, 2025
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practiceMiriam Potrony, Blai Morales-Romero, Lorena Moreno, et al.
Iscience|February 7, 2023
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Antonio Barreiro, Antoni Prenafeta, Gregori Bech-Sabat, et al.
Journal of Youth and Adolescence|April 9, 2025
Global Profiles of Positive Youth Development: A Person-Oriented Analysis among Emerging Adults Living in 21 CountriesJet Uy Buenconsejo, Laura Ferrer-Wreder, Radosveta Dimitrova, et al.
Vaccine|January 14, 2025
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
The Lancet Regional Health. Europe|May 3, 2023
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Pageof 12